AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22045128 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg at the adductor pollicis muscle
Number of subjects: 54
Study 22045128 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg at the orbicularis oris and corrugator supercilii muscles
Number of subjects: 54
Study 20946739 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with community agencies
Number of subjects: 672
Study 20946739 — intervention group
Group type: EXPERIMENTAL
Intervention: Going to Alcoholics Anonymous (AA)
Number of subjects: 672
Study 20946739 — intervention group
Group type: COMPARATOR
Intervention: Heavy-drinking network
Number of subjects: 672
Study 20946739 — intervention group
Group type: COMPARATOR
Intervention: Receiving suggestions to do something about one's drinking
Number of subjects: 672
Study 20946739 — intervention group
Group type: COMPARATOR
Intervention: Going to treatment
Number of subjects: 672
Study 17429677 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐s Wingate anaerobic test (20‐WAT)
Number of subjects: 50
Study 17429677 — intervention group
Group type: COMPARATOR
Intervention: 30‐s Wingate anaerobic test (30‐WAT)
Number of subjects: 50
Study 15297081 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic preparation (Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus with oligofructose)
Number of subjects: 90
Study 15297081 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 90
Study 15297081 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic preparation
Number of subjects: 90
Study 11720813 — intervention group
Group type: EXPERIMENTAL
Intervention: LKM512 yogurt
Number of subjects: 0
Study 9399419 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine stimulation test
Number of subjects: 42
Study 9399419 — intervention group
Group type: COMPARATOR
Intervention: Screening spirometry
Number of subjects: 42
Study 7959544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients
Number of subjects: 47
Study 7959544 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 47
Study 3301154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dezocine (10 mg)
Number of subjects: 60
Study 3301154 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (2 mg)
Number of subjects: 60
Study 3301154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30471138 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine with nevirapine
Number of subjects: 150
Study 30471138 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine without artemether-lumefantrine
Number of subjects: 150
Study 27624173 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg Bevacizumab plus 300 µg/0.1 mL Diclofenac (IVB/D)
Number of subjects: 80
Study 27624173 — intervention group
Group type: COMPARATOR
Intervention: 1.25 mg intravitreal Bevacizumab (IVB)
Number of subjects: 80
Study 27297370 — intervention group
Group type: EXPERIMENTAL
Intervention: Child‐ and Parent‐focused Violence Intervention Program (experimental group)
Number of subjects: 69
Study 27297370 — intervention group
Group type: COMPARATOR
Intervention: Routine psychiatric care (control group)
Number of subjects: 69
Study 25445103 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml of EMLA (lidocaine-prilocaine cream)
Number of subjects: 100
Study 25445103 — intervention group
Group type: COMPARATOR
Intervention: 3 ml of placebo
Number of subjects: 100
Study 22044111 — intervention group
Group type: EXPERIMENTAL
Intervention: GT/Profile protocol
Number of subjects: 0
Study 22044111 — intervention group
Group type: EXPERIMENTAL
Intervention: RaCe/NiTi protocol
Number of subjects: 0
Study 22044111 — intervention group
Group type: COMPARATOR
Intervention: N/A (comparison of techniques)
Number of subjects: 0
Study 19225139 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate and betaine treatment
Number of subjects: 73
Study 19225139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 17890873 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) patients
Number of subjects: 249
Study 17890873 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 249
Study 16212799 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 122
Study 16212799 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole
Number of subjects: 122
Study 16212799 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole and mebendazole (combined results)
Number of subjects: 122
Study 11979067 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of nicotine polacrilex
Number of subjects: 13
Study 11979067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11979067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine treatment
Number of subjects: 13
Study 11979067 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nicotine
Number of subjects: 13
Study 10396215 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 10
Study 7594291 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection with lidocaine
Number of subjects: 24
Study 7594291 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection with lidocaine
Number of subjects: 24
Study 2329813 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of total triterpenic fraction of Centella asiatica (30 mg)
Number of subjects: 12
Study 2329813 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of total triterpenic fraction of Centella asiatica (60 mg)
Number of subjects: 12
Study 2329813 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with total triterpenic fraction of Centella asiatica (30 mg twice daily for 7 days)
Number of subjects: 12
Study 2329813 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with total triterpenic fraction of Centella asiatica (60 mg twice daily for 7 days)
Number of subjects: 12
Study 6990745 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation isoetharine hydrochloride
Number of subjects: 269
Study 6990745 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine
Number of subjects: 269
Study 6990745 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline sulfate
Number of subjects: 269
Study 31276265 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate (MF) cream + LA‐Cer‐containing moisturizer
Number of subjects: 0
Study 31276265 — intervention group
Group type: COMPARATOR
Intervention: 0.1% mometasone furoate (MF) cream
Number of subjects: 0
Study 28142364 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Transtheoretical Model Intervention (ETMI)
Number of subjects: 220
Study 28142364 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy (Control)
Number of subjects: 220
Study 26278876 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed Nutrition Facts label
Number of subjects: 273
Study 26278876 — intervention group
Group type: COMPARATOR
Intervention: Current Nutrition Facts label
Number of subjects: 273
Study 23472458 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Argan Oil (VAO) for 3 weeks
Number of subjects: 60
Study 23472458 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVO) for 3 weeks
Number of subjects: 60
Study 21208922 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of varicella vaccine
Number of subjects: 211
Study 21208922 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of varicella vaccine
Number of subjects: 211
Study 21208922 — intervention group
Group type: EXPERIMENTAL
Intervention: No varicella vaccine
Number of subjects: 211
Study 19948038 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 246
Study 19948038 — intervention group
Group type: COMPARATOR
Intervention: dihydroartemisinin-piperaquine (DP)
Number of subjects: 246
Study 17267326 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg/day
Number of subjects: 206
Study 17267326 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 206
Study 15310086 — intervention group
Group type: EXPERIMENTAL
Intervention: Megamin (3.6 g daily for 6 to 8 weeks)
Number of subjects: 61
Study 15310086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopenomin (1.2 g daily for 6 to 8 weeks)
Number of subjects: 61
Study 12520630 — intervention group
Group type: EXPERIMENTAL
Intervention: ReN1869 (3.5 to 95 mg)
Number of subjects: 56
Study 12520630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 12520630 — intervention group
Group type: EXPERIMENTAL
Intervention: ReN1869
Number of subjects: 56
Study 9686500 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentration of PIIINP in MPD patients
Number of subjects: 48
Study 9686500 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary osteomyelofibrosis patients
Number of subjects: 48
Study 9686500 — intervention group
Group type: EXPERIMENTAL
Intervention: MPD patients
Number of subjects: 48
Study 9686500 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentration of PIIINP
Number of subjects: 48
Study 7928669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor only (V) freezing method
Number of subjects: 19
Study 7928669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor for 12 minutes followed by submersion into liquid nitrogen (V+N2) freezing method
Number of subjects: 19
Study 7928669 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct submersion into liquid nitrogen (N2) freezing method
Number of subjects: 19
Study 7928669 — intervention group
Group type: COMPARATOR
Intervention: Fresh samples
Number of subjects: 19
Study 2528841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg t.i.d. for 1 month, 40 mg t.i.d. thereafter; n = 63 patients)
Number of subjects: 173
Study 2528841 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 84 patients)
Number of subjects: 173
Study 756476 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychotherapy and behavior therapy
Number of subjects: 27
Study 756476 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 27
Study 30945994 — intervention group
Group type: EXPERIMENTAL
Intervention: Valgus knee brace and lateral wedge insole (combined)
Number of subjects: 21
Study 30945994 — intervention group
Group type: COMPARATOR
Intervention: Valgus knee brace (isolation)
Number of subjects: 21
Study 30945994 — intervention group
Group type: COMPARATOR
Intervention: Lateral wedge insole (isolation)
Number of subjects: 21
Study 30945994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined usage of both interventions
Number of subjects: 21
Study 30395189 — intervention group
Group type: EXPERIMENTAL
Intervention: BiXGBoost
Number of subjects: 0
Study 30395189 — intervention group
Group type: COMPARATOR
Intervention: Random forest-based methods
Number of subjects: 0
Study 28851088 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-DAG (2.5 g/d for 12 weeks)
Number of subjects: 114
Study 28851088 — intervention group
Group type: COMPARATOR
Intervention: ALA-TAG (2.5 g/d for 12 weeks)
Number of subjects: 114
Study 23837534 — intervention group
Group type: EXPERIMENTAL
Intervention: Development plan intended to enhance user participation implemented in the intervention hospital.
Number of subjects: 1651
Study 23837534 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (no specific intervention mentioned).
Number of subjects: 1651
Study 21450580 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT)
Number of subjects: 88
Study 21450580 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training (MIT)
Number of subjects: 88
Study 21450580 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 20615317 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush build-up schedule with Depigoid-SCIT (0.2 mL on day 1, 0.3 mL on day 1, 0.5 mL on day 28)
Number of subjects: 303
Study 20615317 — intervention group
Group type: COMPARATOR
Intervention: Conventional 4-week build-up schedule
Number of subjects: 303
Study 18488201 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐ketamine (NMDA antagonist)
Number of subjects: 15
Study 18488201 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT (5HT2A agonist)
Number of subjects: 15
Study 16170235 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (6 mg/70 kg)
Number of subjects: 9
Study 16170235 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (1 and 2 mg/70 kg)
Number of subjects: 9
Study 16170235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12574201 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0
Study 12574201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10573698 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR diagnosis using IS6110 amplification
Number of subjects: 143
Study 8542104 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 6 mg twice per day
Number of subjects: 193
Study 8542104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 1922236 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with cyclophosphamide, methotrexate, and fluorouracil
Number of subjects: 250
Study 1922236 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further treatment) followed by reinduction therapy with cyclophosphamide, methotrexate, and fluorouracil
Number of subjects: 250
Study 1922236 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinduction therapy with cyclophosphamide, methotrexate, and fluorouracil
Number of subjects: 250
Study 1922236 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for maintenance therapy group
Number of subjects: 250
Study 1922236 — intervention group
Group type: COMPARATOR
Intervention: Overall survival for observation group
Number of subjects: 250
Study 1922236 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for all patients
Number of subjects: 250
Study 1922236 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 250
Study 6405607 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper supplement (80 micrograms/kg/day as sulphate)
Number of subjects: 27
Study 6405607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31651324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone treatment
Number of subjects: 277
Study 30488504 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin‐polyaldehyde sealant applied to pharyngeal repair
Number of subjects: 45
Study 30488504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sealant)
Number of subjects: 45
Study 27113884 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin‐dextran
Number of subjects: 48
Study 27113884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic riboflavin
Number of subjects: 48
Study 25440482 — intervention group
Group type: COMPARATOR
Intervention: UHC
Number of subjects: 56197
Study 25440482 — intervention group
Group type: EXPERIMENTAL
Intervention: NSQIP
Number of subjects: 56197
Study 21982106 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (2.5 mg/0.1 mL)
Number of subjects: 36
Study 21982106 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (0.02% for 3 minutes)
Number of subjects: 36
Study 21982106 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IOP between groups
Number of subjects: 36
Study 19557167 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt weaning at 4 months
Number of subjects: 958
Study 19557167 — intervention group
Group type: COMPARATOR
Intervention: Continued breastfeeding
Number of subjects: 958
Study 19557167 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt weaning at 4 months (mothers with less severe disease)
Number of subjects: 958
Study 19557167 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt weaning at 4 months (mothers with more severe disease)
Number of subjects: 958
Study 19557167 — intervention group
Group type: COMPARATOR
Intervention: Weaning before 15 months (control group)
Number of subjects: 958
Study 17956917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise training (IET) for 3 weeks after hospital discharge
Number of subjects: 0
Study 17956917 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 16891588 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-mg hydrocortisone
Number of subjects: 27
Study 16891588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15459246 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1.5 mg)
Number of subjects: 8
Study 15459246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10910871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg melatonin
Number of subjects: 84
Study 10910871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg melatonin
Number of subjects: 84
Study 10910871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg melatonin
Number of subjects: 84
Study 10910871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg midazolam
Number of subjects: 84
Study 10910871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam
Number of subjects: 84
Study 10910871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg midazolam
Number of subjects: 84
Study 10910871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 8725276 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 14
Study 8725276 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (79% He, 21% O2)
Number of subjects: 14
Study 8725276 — intervention group
Group type: COMPARATOR
Intervention: Comparison of heliox and oxygen
Number of subjects: 14
Study 1313637 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg on the first day followed by 250 mg once a day for 4 days
Number of subjects: 57
Study 1313637 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg and probenecid 500 mg, three times a day for 10 days
Number of subjects: 57
Study 1313637 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline, 100 mg twice a day for 10 days
Number of subjects: 57
Study 1313637 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/probenecid or doxycycline extended treatment if symptoms were still present at 10 days
Number of subjects: 57
Study 1313637 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effectiveness of the three regimens
Number of subjects: 57
Study 3905440 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV (1, 2‐diphenyl‐alpha beta‐diketone)
Number of subjects: 152
Study 3905440 — intervention group
Group type: EXPERIMENTAL
Intervention: herbs
Number of subjects: 152
Study 3905440 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 152
Study 31647425 — intervention group
Group type: EXPERIMENTAL
Intervention: JSR-ES (joint spectral reconstruction with energy-window subset algorithm)
Number of subjects: 0
Study 31647425 — intervention group
Group type: EXPERIMENTAL
Intervention: JSR-ES
Number of subjects: 0
Study 31647425 — intervention group
Group type: COMPARATOR
Intervention: Multi-band forward modeling with a single acquisition window
Number of subjects: 0
Study 31647425 — intervention group
Group type: COMPARATOR
Intervention: Single-band forward modeling with a single acquisition window
Number of subjects: 0
Study 31929849 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 62
Study 31929849 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen administration
Number of subjects: 62
Study 28743821 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐‐rich beetroot juice (BR; providing 8.4 mmol NO3‐∙day‐1)
Number of subjects: 8
Study 28743821 — intervention group
Group type: COMPARATOR
Intervention: NO3‐‐depleted beetroot juice (placebo; PLA)
Number of subjects: 8
Study 26518021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral stress management (CBSM) intervention, 10-week, group-based
Number of subjects: 240
Study 26518021 — intervention group
Group type: COMPARATOR
Intervention: 1‐day psychoeducational seminar
Number of subjects: 240
Study 23085891 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent regular diets
Number of subjects: 100
Study 23085891 — intervention group
Group type: COMPARATOR
Intervention: Alternating diets (2 different complete chows)
Number of subjects: 100
Study 21865203 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥30 kg/m2
Number of subjects: 6560
Study 21865203 — intervention group
Group type: COMPARATOR
Intervention: BMI <25 kg/m2
Number of subjects: 6560
Study 21865203 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI groups stratified by WC
Number of subjects: 6560
Study 21865203 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day to 1-year outcomes
Number of subjects: 6560
Study 19118301 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine perfusion
Number of subjects: 672
Study 19118301 — intervention group
Group type: COMPARATOR
Intervention: Cold storage
Number of subjects: 672
Study 17208082 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low-molecular-weight heparin (LMWH) therapy (tinzaparin)
Number of subjects: 737
Study 17208082 — intervention group
Group type: COMPARATOR
Intervention: Usual care (vitamin K antagonist therapy)
Number of subjects: 737
Study 15389185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 141
Study 15389185 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 141
Study 11524191 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine hydrochloride 2% (5 doses, 2 drops per dose) before phacoemulsification and foldable IOL implantation
Number of subjects: 388
Study 11524191 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine hydrochloride 2%
Number of subjects: 388
Study 11524191 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with cataract and no glaucoma)
Number of subjects: 388